Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma

BACKGROUND: Metastatic upper tract urothelial carcinoma (mUTUC) is a malignant cancer associated with poor prognosis. Few studies have investigated the clinical outcome of a recently developed combination regimen of programmed cell death 1 (PD-1) inhibitor plus nab-paclitaxel in mUTUC. METHODS: We r...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Ruopeng, Chen, Zeyu, Hu, Hailong, Jiang, Shuai, Chen, Minfeng, Chen, Qiong, Gellhaus, Paul Thomas, Ornellas, Antonio Augusto, Campobasso, Davide, Wei, Qiang, Huang, Jiwei, Bao, Yige, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560336/
https://www.ncbi.nlm.nih.gov/pubmed/37814696
http://dx.doi.org/10.21037/tau-23-404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560336/
https://www.ncbi.nlm.nih.gov/pubmed/37814696
http://dx.doi.org/10.21037/tau-23-404

Ejemplares similares